Abstract:Targeted anticancer drugs block cancer cell growth by interfering with specific signaling pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing cells as in cytotoxic chemotherapy. The Response Evaluation Criteria in Solid Tumor (RECIST) system has been used to assess tumor response to therapy via changes in the size of target lesions as measured by calipers, conventional anatomically based imaging modalities such as computed tomography (CT), and magnetic resonance imaging (MRI), and other imaging methods. However, RECIST is sometimes inaccurate in assessing the efficacy of targeted therapy drugs because of the poor correlation between tumor size and treatment-induced tumor necrosis or shrinkage. This approach might also result in delayed identification of response when the therapy does confer a reduction in tumor size. Innovative molecular imaging techniques have rapidly gained importance in the dawning era of targeted therapy as they can visualize, characterize, and quantify biological processes at the cellular, subcellular, or even molecular level rather than at the anatomical level. This review summarizes different targeted cell signaling pathways, various molecular imaging techniques, and developed probes. Moreover, the application of molecular imaging for evaluating treatment response and related clinical outcome is also systematically outlined. In the future, more attention should be paid to promoting the clinical translation of molecular imaging in evaluating the sensitivity to targeted therapy with biocompatible probes. In particular, multimodal imaging technologies incorporating advanced artificial intelligence should be developed to comprehensively and accurately assess cancer-targeted therapy, in addition to RECIST-based methods.

Research progresses on the functional polypeptides in the detection and imaging of breast cancer

Research Progresses on the Functional Polypeptides in the Detection and Imaging of Breast Cancer.

Recent Development on Peptide-Based Probes for Multifunctional Biomedical Imaging

Recent progress in functional peptides designed for tumor-targeted imaging and therapy

Molecular Imaging Using PET and SPECT for Identification of Breast Cancer Subtypes

Application of functional peptides in the electrochemical and optical biosensing of cancer biomarkers

Recent Progress in Peptide-Based Molecular Probes for Disease Bioimaging

Research Progress on Tumor-Targeting Immunoconjugate

Peptide‐Based Multifunctional Nanomaterials for Tumor Imaging and Therapy

Peptide-based nanoprobes for molecular imaging and disease diagnostics

Research progress of molecular nuclear medicine imaging in breast cancer

Polypeptides-Based Nanocarriers in Tumor Therapy

Peptide Biomarkers - An Emerging Diagnostic Tool and Current Applicable Assay

Molecular Imaging Probes for Diagnosis and Therapy Evaluation of Breast Cancer

Recent Progress of Multifunctional Molecular Probes for Triple-Negative Breast Cancer Theranostics

Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors

Application of Intelligent Response Fluorescent Probe in Breast Cancer

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Recent advances in anticancer peptoids

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions

Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy